Search Results - "Shemesh CS"

Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.

Authors: Shemesh CS Wang Y An A et al.

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Jul; Vol. 94 (1), pp. 45-55. Date of Electronic Publication: 2024 Mar 07.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).

Authors: Garralda E Oh DY Italiano A et al.

Source: Journal of clinical pharmacology [J Clin Pharmacol] 2024 May; Vol. 64 (5), pp. 544-554. Date of Electronic Publication: 2024 Jan 17.

Publication Type: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

Applying Natural Language Processing to ClinicalTrials.gov: mRNA cancer vaccine case study.

Authors: Vora B Kuruvilla D Kim C et al.

Source: Clinical and translational science [Clin Transl Sci] 2023 Dec; Vol. 16 (12), pp. 2417-2420. Date of Electronic Publication: 2023 Oct 12.

Publication Type: Journal Article

Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE

Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.

Authors: Shemesh CS Chan P Marchand M et al.

Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Sep; Vol. 114 (3), pp. 644-651. Date of Electronic Publication: 2023 Jun 02.

Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.

Authors: Ko AH Kim KP Siveke JT et al.

Source: The oncologist [Oncologist] 2023 Jun 02; Vol. 28 (6), pp. 553-e472.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

Authors: Finn RS Ryoo BY Hsu CH et al.

Source: The Lancet. Oncology [Lancet Oncol] 2025 Feb; Vol. 26 (2), pp. 214-226. Date of Electronic Publication: 2025 Jan 21.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.

Authors: Huang W Stader F Chan P et al.

Source: Frontiers in pharmacology [Front Pharmacol] 2022 Sep 26; Vol. 13, pp. 974423. Date of Electronic Publication: 2022 Sep 26 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.

Authors: Kristeleit R Leary A Oaknin A et al.

Source: British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (5), pp. 820-831. Date of Electronic Publication: 2024 Jul 06.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Authors: Shemesh CS Chan P Shao H et al.

Source: Liver cancer [Liver Cancer] 2021 Jun 10; Vol. 10 (5), pp. 485-499. Date of Electronic Publication: 2021 Jun 10 (Print Publication: 2021).

Publication Type: Journal Article

Journal Info: Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: eCollection Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.

Authors: Lu D Lu T Shi R et al.

Source: Pharmaceutical research [Pharm Res] 2020 Dec 01; Vol. 37 (12), pp. 252. Date of Electronic Publication: 2020 Dec 01.

Publication Type: Journal Article

Journal Info: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-904X (Electronic) Linking ISSN: 07248741 NLM ISO Abbreviation: Pharm Res Subsets: MEDLINE

Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).

Authors: Drakaki A Powles T Bamias A et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 01; Vol. 29 (21), pp. 4373-4384.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.

Authors: Shemesh CS Agarwal P Lu T et al.

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 May; Vol. 85 (5), pp. 831-842. Date of Electronic Publication: 2020 Mar 28.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.

Authors: Lemaire V Shemesh CS Rotte A

Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2021 Oct 01; Vol. 40 (1), pp. 311. Date of Electronic Publication: 2021 Oct 01.

Publication Type: Journal Article; Review

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.

Authors: Shemesh CS Hsu JC Hosseini I et al.

Source: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2021 Feb 03; Vol. 29 (2), pp. 555-570. Date of Electronic Publication: 2020 Sep 30.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE

Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.

Authors: Shemesh CS Chan P Legrand FA et al.

Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2020 Dec; Vol. 8 (6), pp. e00685.

Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE

Thermosensitive liposome formulated indocyanine green for near-infrared triggered photodynamic therapy: in vivo evaluation for triple-negative breast cancer.

Authors: Shemesh CS Moshkelani D Zhang H

Source: Pharmaceutical research [Pharm Res] 2015 May; Vol. 32 (5), pp. 1604-14. Date of Electronic Publication: 2014 Nov 19.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-904X (Electronic) Linking ISSN: 07248741 NLM ISO Abbreviation: Pharm Res Subsets: MEDLINE

Near-infrared image-guided delivery and controlled release using optimized thermosensitive liposomes.

Authors: Turner DC Moshkelani D Shemesh CS et al.

Source: Pharmaceutical research [Pharm Res] 2012 Aug; Vol. 29 (8), pp. 2092-103. Date of Electronic Publication: 2012 Mar 27.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-904X (Electronic) Linking ISSN: 07248741 NLM ISO Abbreviation: Pharm Res Subsets: MEDLINE

Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.

Authors: Geoerger B Zwaan CM Marshall LV et al.

Source: The Lancet. Oncology [Lancet Oncol] 2020 Jan; Vol. 21 (1), pp. 134-144. Date of Electronic Publication: 2019 Nov 25.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.

Authors: Lu D Lu T Gibiansky L et al.

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2020 Jan; Vol. 9 (1), pp. 48-59. Date of Electronic Publication: 2019 Dec 23.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.

Authors: Shemesh CS Chanu P Jamsen K et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Nov 21; Vol. 7 (1), pp. 314. Date of Electronic Publication: 2019 Nov 21.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE